26 C
New York

Tag: segment

Questions to Ask Your Car Mechanic & Important PickUp Truck Replacement Parts

Servicing your car every six months or yearly is necessary to keep it fit and ready for the road. Above that, it helps you...

Top News

ADDX tokenises private equity fund of funds

The SGX-backed private market exchange has partnered with Fullerton Fund Management to allow tokenised access to the Fullerton Optimised Alpha Fund SINGAPORE, 11 MAY 2022...

Watch live: Russian cosmonauts begin 250th space station spacewalk

Russian cosmonauts Oleg Artemyev and Denis Matveev ventured outside the International Space Station on Thursday for a planned six-and-a-half hour spacewalk to begin unlimbering the European Robotic Arm.

TUNGSRAM: innovation is in our bloodstream

Tungsram – an iconic name – returned to the global market in 2018 as an innovative, premium European brand with the acquisition of GE Lighting’s Europe, Middle East, Africa, and Turkey general lighting business along with the global automotive operation. Tungsram, originally established in 1896, is a brainchild of the 2nd industrial revolution – resulting […]

The post TUNGSRAM: innovation is in our bloodstream appeared first on Aerospace.

Catalyst = 20% lower consumption & 10% higher power for Eurodrone

Catalyst – 100% European development without any US licenses. Ecologically more effective thanks to 20% lower consumption and 10% higher power. This means three more hours of time in the air,  which can be decisive in various defense actions and even save lives.     Within a few weeks, Airbus Defense and Space will have […]

The post Catalyst = 20% lower consumption & 10% higher power for Eurodrone appeared first on Aerospace.

US DoD Unmanned Aerial Vehicles Report 2021-2025: Market Participants, Customers, and Department of Defense (DoD) Agencies that Influence the Industry – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “US DoD Unmanned Aerial Vehicles Growth Opportunities” report has been added to ResearchAndMarkets.com’s offering. This research service focuses on the US military unmanned aerial vehicles (UAVs) market. The base year for spending information is 2021, and example market participants and market size estimates for the years 2021 to 2025 are provided. This study […]

The post US DoD Unmanned Aerial Vehicles Report 2021-2025: Market Participants, Customers, and Department of Defense (DoD) Agencies that Influence the Industry – ResearchAndMarkets.com appeared first on Fintech News.

OLB Group Inc. to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28, 2022 at 4:15 p.m. Eastern Time

NEW YORK–(BUSINESS WIRE)–The OLB Group, Inc. (NASDAQ: OLB) (“OLB”, the “Company”), an emerging FinTech company leveraging proprietary omnicommerce and blockchain technology to build customized payment solutions, will release financial results for the fourth quarter and full year ended December 31, 2021 after market close on Monday March 28, 2022. Management will host a conference call […]

The post OLB Group Inc. to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28, 2022 at 4:15 p.m. Eastern Time appeared first on Fintech News.

Tag Template - News Hub PRO

The coolest thing I saw at GDC: software that animates anything

Tell Anything World what you want, and it tries to make it happen using machine learning and over 500,000 3D models.

Sands China Provided $40M in Macau Mall Rent Aid Last Year, Down 81 Percent

Sands China Ltd., the Macau arm of Las Vegas Sands (NYSE:LVS), said it provided $41 million in rental assistance last year to tenants at its mall shops in the special administrative region (SAR). The total was needed because of the pandemic, but marked an improvement in revenue rom 2020. In a regulatory filing with the […]

The post Sands China Provided $40M in Macau Mall Rent Aid Last Year, Down 81 Percent appeared first on Casino.org.

Rocket League’s race to become a Tier 1 esport

For a game where flying rocket-powered battle cars slam oversized low-gravity footballs into virtual nets, Rocket League is surprisingly skillful. Like any skill-based competitive pursuit, setting is largely irrelevant — winning requires mastery, and mastery warrants practice. Like all esports titles, Rocket League requires thousands of hours spent training and refining intricate mechanical movements, the […]

Brian Reisbeck of Coinme Discusses International Efforts to Regulate Crypto

Brian Reisbeck is the new chief compliance officer at Coinme, a crypto exchange stationed in the U.S. He recently offered his comments and thoughts on international compliance and attempts to regulate the crypto space. Brian Reisbeck Offers His Thoughts on Crypto Compliance Regulation has long been a controversial topic, with some analysts completely for it,...

The post Brian Reisbeck of Coinme Discusses International Efforts to Regulate Crypto appeared first on Live Bitcoin News.

Kindstar Globalgene Announces FY2021 Annual Results, Revenue Increases to RMB930.67 Million

Tag Template - News Hub PRO

HONG KONG, Mar 25, 2022 - (ACN Newswire) - Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 9960.HK), a leading independent esoteric clinical testing service provider in China, today announced its audited annual results for the year ended 31 December 2021 ("2021" or the "Year").

During the period under review, the Group recorded total revenue of RMB930.67 million, representing a year-on-year increase of 4.4%. Revenue from non-COVID-19-related testing services was RMB868.57 million, an increase of 12.3%. The Group's consolidated gross profit was up by 5.4% year-on-year to RMB485.77 million, while the consolidated gross profit margin rose by 0.5% year-on-year to 52.2%. Cash and cash equivalents amounted to RMB1,796.7 million, a growth of 113.6% year-on-year. The non-COVID-19-related testing services segment recorded results of RMB197.18 million, an increase of 17.5% year-on-year. The Board has resolved not to distribute a dividend for FY2021.

Focused on specialty esoteric testing services and vigorously developed related services in six major specialty areas

Since its inception in 2003, the Group has been focusing on esoteric clinical testing services and is one of the first companies in China entering the esoteric testing service industry. During the period under review, the Group covered more than 3000 hospitals, in which over 60% are Class III hospitals, added three new laboratories and its esoteric testing volume exceeded 1.68 million, with positive growth in all six major esoteric testing specialty areas.

-- Hematology testing: The Group introduced 50 new testing items and added the Shanghai Xinnuo Baishi Medical Laboratory. During the period, the Group achieved revenue of RMB535.27 million and segment results of RMB152.57 million, representing a year-on-year increase of 14% and 15.7%, respectively.
-- Neurology testing: The Group launched six new projects covering diseases such as Alzheimer's disease and myasthenia [gravis] and also added 143 partnering Class III hospitals. The Group recorded revenue of RMB89.85 million and segment results of RMB14.06 million during the period, a year-on-year increase of 18.2 and 11.6%, respectively.
-- Maternity-related testing: The Group added the diagnosis of gestational syndromes during the period, and recorded revenue of RMB52.25 million and segment results of RMB3.55 million, representing a year-on-year increase of 0.2% and 0.5%, respectively.
-- Genetic disease and rare disease testing: During the period, the Group realized revenue of RMB43.50 million and segment results of RMB5.43 million, representing a year-on-year increase of 20.2% and 126.4%, respectively. Sales of multiple steroid hormone tests doubled year-on-year.
-- Infectious disease testing: The Group introduced 28 new testing items and added the Wuhan Kindstar Zhenyuan Medical Laboratory, achieving revenue of RMB51.97 million and segment results of [RMB]9.78 million during the period, representing a year-on-year increase of 3% and 33.2%, respectively.
-- Oncology testing: The Group launched new testing service items for various types of cancer, including intestinal cancer, cervical cancer, bladder cancer and liver cancer, achieving revenue of RMB8.62 million and segment results of RMB0.83 million during the period, 13.4% and 82.5% higher than the same period last year.
-- Others: The Group added more than 20 scientific research service projects in the areas of research services, CRO and new testing services, achieving revenue of RMB19.46 million and segment results of RMB5.99 million during the period, representing a year-on-year growth of 36.1% and 35.1%, respectively.

Persistent R&D investment to develop and expand new specialty esoteric testing business lines

As at 31 December 2021, the Group's R&D expenses amounted to RMB90.33 million, a year-on-year increase of 20.0%.The Group had 112 new R&D projects, 17 patents were pending or granted and 23 scientific research articles were published throughout the year. During the period under review, the Group stepped up its efforts in promoting the development of specialty esoteric testing services in China and expanding the scope of such services to cover cardiovascular diseases, ophthalmology, rheumatology and immunology.

-- Cardiovascular diseases: The Group focused on the R&D of biomarkers for cardiovascular diseases such as coronary heart disease, acute myocarditis and acute myocardial infarction. It also conducted verification studies on the clinical value of biomarkers.
-- Ophthalmology: The Group actively explored opportunities in ophthalmic structured esoteric testing services and its R&D covered testing solutions for hereditary oculopathy, infectious oculopathy and autoimmune oculopathy.
-- Rheumatology and immunology: The Group began the initial development of six types of disease and drug detection projects, covering sicca syndrome, rheumatoid arthritis, ankylosing spondylitis, gout, antiphospholipid syndrome and allopurinol detection.

Entered the IVD reagents field and optimized immune repertoire deployment

Wuhan Haixi Life Science Technology Co., Ltd., which the group owns a controlling stake, is a high-tech enterprise based on the R&D, manufacturing and sales of esoteric testing reagents providing systematic, comprehensive "high-precision and cutting edge" testing reagent products. The Group's main products, namely reagent kits for JAK2 genes and V617F mutations (PCR-fluorescent probe method) and reagent kits for leukemia fusion genes qualitative testing (PCR-fluorescent probe method) will enter the clinical trial stage of NMPA registration. During the period under review, the Group established its business presence in the field of IVD reagent kits in the upstream industry chain by holding shares in Wuhan Haixi Life Science Technology Co., Ltd.

As an important next-generation sequencing technology, the immune repertoire sequencing technology may bring disruptive changes to the industry in the future. During the period under review, the Group established Wuhan Kindstar Biotechnology Co., Ltd., which will focus on the application and development of the immune repertoire technology in multiple disciplines and explore the biopharmaceutical and immunotherapy pathways. In addition, to further improve its immune repertoire layout, the Group invested in Shenzhen Neoimmune Co., Ltd., a leading immune repertoire enterprise in China. Looking ahead, the two parties will commence strategic cooperation in the immune repertoire segment.

Strategy and Prospects

The Group will continue to consolidate its leading position in esoteric hematology testing in China and replicate its successful experience in hematology to expedite the growth of its specialty esoteric testing business in areas such as genetic diseases, rare diseases, infectious diseases, oncology and neurology. In the next three to five years, the Group will enter several new areas of specialty esoteric testing. At the same time, the Group is also committed to building strong relationships with a wide range of participants in the clinical esoteric testing industry (including doctors, hospitals, pharmaceutical companies, contract research institutions, academic institutions and regulatory agencies), deepening existing strategic partnerships, and expanding the existing cooperation network. Since its listing, the Group has attached great importance to opportunities for horizontal and vertical integration in the industrial chain. In the future, the Group will steadily achieve a strategic and forward-looking layout through investment, integration and empowerment, in order to boost its growth.

Huang Shiang, Chairman and Chief Executive Officer of Kindstar Globalgene, expressed full confidence in the future of China's esoteric clinical testing industry. He said, "Due to increasing public health awareness and an aging population in China, the demand for clinical tests has continued to increase. In recent years, China's esoteric clinical testing market has been growing faster than its routine testing market, and the Company has strived to develop and introduce advanced technologies to meet the enormous unmet medical demand in the country. Looking ahead, we will actively overcome the various uncertainties caused by the COVID-19 pandemic, while continuing to work hard to maintain the steady growth of our existing esoteric clinical tests, and develop and launch new services in specialty areas, thereby contributing to the precise diagnosis and advancement of treatments in specialty areas in China."

Kindstar Globalgene 2021 Annual Results Announcement:
https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0325/2022032501238.pdf

Infographics for Kindstar Globalgene 2021 Annual Results Announcement:
https://mp.weixin.qq.com/s/h1rKtS_79dJ-Symd7Prz0w

About Kindstar Globalgene Technology, Inc.
Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Group"; stock code: 9960.HK) is a leading independent esoteric clinical testing service provider and a major provider of hematology esoteric testing services in China. It has built a comprehensive testing portfolio, a broad hospital network and advanced technology platforms and also boasts the largest esoteric testing portfolio among all independent esoteric testing providers in China, with more than 3,500 tests on its service menu and offering one of the most extensive hematology testing portfolios worldwide, including over 2,300 testing items in the field. The Group primarily targets specialty areas with substantial growth potential or that can create significant synergies with its esoteric hematology testing services, including genetic diseases and rare diseases, infectious diseases, oncology and neurology. The Group was listed on the Main Board of the Hong Kong Stock Exchange on 16 July 2021. Over the past 18 years, the Company has developed more than 1,100 testing items entirely in-house, and introduced approximately 2,400 testing items developed by or under license from third parties. The Group serves more than 3,000 hospitals in China, of which more than 1,500 are Class III hospitals, including all of the top 20 hospitals in the nation. The Group's mission is to offer a broad range of high-quality specialty testing services to patients and physicians worldwide, and to promote the application of precision diagnostics and medicine.

The Group's website: https://www.kindstar.com.cn/tc/



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comKindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 9960.HK), a leading independent esoteric clinical testing service provider in China, today announced its audited annual results for the year ended 31 December 2021 ("2021" or the "Year").

Can On-Chain Indicators Call Tops And Bottoms For The Bitcoin Price?

Analyzing seven key on-chain indicators can give us major hints as to when the bitcoin price is at the top or bottom of the current market cycle.
Tag Template - News Hub PRO

Recent articles

spot_img